Bronchiectasis Epidemiology

Bronchiectasis Insights and Trends

• Bronchiectasis is a chronic, progressive respiratory disease characterized by irreversible bronchial dilatation, persistent airway inflammation, recurrent infections, and impaired mucociliary clearance, resulting in substantial morbidity, reduced quality of life, frequent exacerbations, and increased healthcare utilization.
• As per DelveInsight research, more than 1 million diagnosed prevalent cases of bronchiectasis were reported across the 7MM in 2025. The patient population is expected to grow significantly through 2036, driven by improved disease recognition, broader use of HRCT, aging populations, and increasing prevalence of underlying chronic respiratory and systemic conditions.
• Bronchiectasis epidemiology is highly heterogeneous, encompassing both non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis bronchiectasis (CFB), with NCFB accounting for the overwhelming majority of cases. Variability in underlying etiology, disease severity, microbiological colonization, and clinical presentation continues to complicate accurate assessment of disease burden across populations.
• The continued dominance of Pseudomonas aeruginosa across microbiological in NCFB analyses reinforces its role as more than a pathogen marker. Its association with exacerbation frequency, hospitalization risk, and disease progression suggests that microbiological stratification is becoming increasingly important in understanding disease burden.
• The large proportion of moderate-severity NCFB patients reflects a population that has progressed beyond early disease but has not yet reached advanced structural deterioration. This concentration in the intermediate stage underscores the chronic progressive nature of bronchiectasis and its prolonged clinical trajectory.

DelveInsight's ‘Bronchiectasis – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the United Kingdom
• Asia-Pacific: Japan

Bronchiectasis Understanding

Bronchiectasis Overview and Diagnosis

Bronchiectasis is a chronic lung disease characterized by permanent dilation and damage of the bronchial tubes, leading to impaired mucus clearance, chronic cough, and recurrent lung infections. The condition involves irreversible structural damage, creating a cycle of inflammation and infection that affects lung function and quality of life. Risk factors include prior respiratory infections such as pneumonia and tuberculosis, chronic lung diseases, cystic fibrosis, autoimmune disorders, immune deficiencies, among others.

Bronchiectasis is primarily diagnosed using high-resolution computed tomography (HRCT) of the chest, which is the gold-standard imaging technique for identifying permanent bronchial dilatation and airway wall thickening. The diagnostic workup also includes a detailed clinical history, physical examination, pulmonary function tests (PFTs), and sputum culture to assess lung function and detect chronic airway infections. Additional laboratory tests, such as immunoglobulin levels, autoimmune screening, and evaluation for underlying conditions like cystic fibrosis or allergic bronchopulmonary aspergillosis, may be performed to determine the cause and guide management.

Further details are provided in the report.

Bronchiectasis Epidemiology

Key Findings from Bronchiectasis Epidemiological Analysis and Forecast

• The diagnosed prevalent NCFB population surpassed 1 million cases across the 7MM in 2025, emphasizing the significant epidemiological footprint of the disease and persistent geographic disparities in diagnosis and disease recognition.
• The gender-specific diagnosed prevalent cases of NCFB in the US were estimated at approximately 130,000 cases in males and 260,000 cases in females in 2025, consistent with the broadly comparable gender distribution observed in CF populations.
• In 2025, the microbiology-specific diagnosed prevalent cases of Staphylococcus aureus in CFB patients across the 7MM were estimated at approximately 36,000 cases.

Industry Experts and Physician Views for Bronchiectasis

To keep up with bronchiectasis dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the bronchiectasis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 6+ KOLs to gather insights at country level. Centers such as the University of Santo Tomas, Berlin Institute of Health at Charité , Paris-Est Créteil University, University of Duisburg-Essen etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in bronchiectasis.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of bronchiectasis, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• Bronchiectasis Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of bronchiectasis cases?
• What are the disease risks and burdens of bronchiectasis?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of bronchiectasis at the 7MM level?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.